| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSG5 |
| Uniprot No | Q15238 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-335aa |
| 氨基酸序列 | QVTIEALPPKVSEGKDVLLLVHNLPQNLAGYIWYKGQLMDLYHYITSYVV DGQINIYGPAYTGRETVYSNASLLIQNVTREDAGSYTLHIIKRGDRTRGV TGYFTFNLYLKLPKPYITINNSKPRENKDVLAFTCEPKSENYTYIWWLNG QSLPVSPRVKQPIENRILILPSVTRNETGPYECEIRDRDGGMHSDPVTLN VLYGPDLPSIYPSFTYYRSGENLYLSCFAESNPPAEYFWTINGKFQQSGQ KLSIPQITTKHRGLYTCSVRNSATGKESSKSMTVEVSAPSGIGRLPLLNP IVDHHHHHH |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSG5重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Recombinant PSG5 modulates maternal immune response during pregnancy"*
**作者**：Smith A, et al.
**摘要**：本研究成功表达并纯化了重组PSG5蛋白，证实其通过抑制促炎细胞因子(如TNF-α和IL-6)分泌参与孕期母体免疫耐受调节，为PSG家族蛋白在妊娠免疫微环境中的作用提供了新证据。
2. **文献名称**：*"Structural and functional characterization of human PSG5 recombinant protein"*
**作者**：Zhang Y, et al.
**摘要**：通过哺乳动物表达系统获得高纯度PSG5重组蛋白，解析其N端结构域与整合素受体结合的分子机制，提示PSG5可能通过细胞黏附通路促进胎盘滋养层细胞的功能。
3. **文献名称**：*"PSG5 promotes trophoblast invasion via recombinant protein-mediated ERK signaling activation"*
**作者**：Li X, et al.
**摘要**：实验证明重组PSG5蛋白可激活ERK1/2信号通路，增强滋养层细胞的迁移与侵袭能力，暗示其在胚胎着床及胎盘发育中的潜在作用。
**注**：上述文献为示例，实际研究中PSG5相关论文较少，建议扩展检索PSG家族(如PSG1、PSG9)或结合“pregnancy-specific glycoprotein”与“recombinant expression”等关键词获取更多信息。
**Background of PSG5 Recombinant Protein**
Pregnancy-specific glycoproteins (PSGs) belong to the carcinoembryonic antigen (CEA) family, primarily expressed in placental trophoblasts during pregnancy. Among them, PSG5 (Pregnancy-Specific Glycoprotein 5) is a secreted protein implicated in maternal-fetal immunomodulation, vascular adaptation, and placental development. Structurally, PSG5 consists of an N-terminal immunoglobulin variable (IgV)-like domain and a C-terminal domain, with extensive glycosylation contributing to its functional diversity.
PSG5 is hypothesized to modulate immune responses at the maternal-fetal interface by interacting with receptors on immune cells, such as dendritic cells and macrophages, promoting anti-inflammatory cytokine production (e.g., IL-10) and suppressing pro-inflammatory pathways. This immune tolerance mechanism helps protect the semi-allogeneic fetus from maternal rejection. Additionally, PSG5 may support angiogenesis and trophoblast invasion, critical for placental function.
Recombinant PSG5 is produced using expression systems (e.g., mammalian CHO or HEK293 cells) to ensure proper glycosylation and structural fidelity. Its purified form enables mechanistic studies, such as ligand-receptor interactions (e.g., CD36. heparan sulfate proteoglycans) and signaling pathway analysis. Research highlights its potential therapeutic applications in pregnancy-related disorders (e.g., preeclampsia, recurrent miscarriage) and inflammatory diseases. Furthermore, PSG5’s tumor-associated expression in certain cancers suggests roles in cancer immunology, warranting exploration as a diagnostic or immunotherapeutic target.
Overall, recombinant PSG5 serves as a vital tool for deciphering its biological roles and translational potential in reproductive health and beyond.
×
